NOV 06, 2020 3:30 PM PST

Anti-depressant Shows Promise in Treating Childhood Cancer

WRITTEN BY: Annie Lennon

Researchers from Sweden and the US have found that a commonly prescribed antidepressant may help stop the growth of a cancer known as childhood sarcoma, a disease in which cancer cells form in soft tissues of the body. 

In their study, the researchers looked at commonalities between two large groups of cell surface receptors. The first is known as G protein-coupled receptors (GPCRs) and is targeted by more than half of all developed drugs to treat conditions including allergies, depression, and hypertension. Until now, however, they have not been targeted to treat cancer. 

The second group of cell surface receptors is known as receptor tyrosine kinases (RTKs). These receptors are currently targeted by drugs to treat various cancers, including breast and colon cancer, due to their involvement in a variety of cellular abnormalities. One receptor in this group, known as a insulin-like growth factor receptor (IGF1R), is known to play a key role in a variety of cancers. While some have attempted to use it as a drug target, none have so far succeeded.

In this study, however, the researchers found that IGF1R shares a signaling module with GPCRs. This means that drugs that target GCPRs may be able to affect its function. As such, the researchers decided to repurpose an existing drug to see how it may affect cancer growth. 

In the end, they decided to treat mice infected with childhood sarcoma cells with Paroxetine, an antidepressant that impairs a serotonin reuptake receptor that is a part of the GPCR-family. In doing so, they found that the drug was able to reduce the number of IGF1R receptor cells on the malignant cells, and thus suppress tumor growth. 

"We have developed a novel strategy to control the activity of these tumor-driving receptors by striking the GPCRs," says Leonard Girnita, principal investigator of the study. 

"To our knowledge this represents a new paradigm for the entire class of cancer-relevant RTKs and could be used as a starting point for the rational design of specific therapeutics in virtually any pathological conditions. This is especially important considering the huge number of GPCR-targeting medicines already in clinical use and with low toxicity."

The researchers now hope to develop their strategy to selectively cross-target multiple RTKs to treat cancer. They then hope to test their findings in clinical trials. 

 

Sources: Medical XpressCancer Research

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JAN 01, 2021
Microbiology
A New Type of Antibiotics Help the Immune System Fight Pathogens
JAN 01, 2021
A New Type of Antibiotics Help the Immune System Fight Pathogens
Reporting in Nature, scientists have identified a new group of compounds that may help us get out of the antibiotic-resi ...
JAN 03, 2021
Drug Discovery & Development
How Psychedelic Salvinorin A Works in the Brain
JAN 03, 2021
How Psychedelic Salvinorin A Works in the Brain
Despite increasing interest in hallucinogens, the effects of Salvinorin A, a drug used in Native Mexican rituals, have r ...
JAN 25, 2021
Cancer
Combining Radiotherapy and Immunotherapy in Liver Cancer
JAN 25, 2021
Combining Radiotherapy and Immunotherapy in Liver Cancer
The dream of a magic bullet drug plagues the mind of scientists, doctors, and patients. The truth is some diseases are j ...
FEB 18, 2021
Cell & Molecular Biology
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
FEB 18, 2021
Inhibition of a Specific Enzyme Could be a Way to Treat Glioblastoma
Researchers may have identified a new treatment target for a deadly form of brain cancer. Inhibiting an enzyme called PR ...
FEB 26, 2021
Microbiology
Good Bacteria Fights Bad Bacteria in a Clinical Trial
FEB 26, 2021
Good Bacteria Fights Bad Bacteria in a Clinical Trial
Eczema is a skin condition that causes a chronic, itchy rash. The most common form of the disorder, atopic dermatitis, i ...
FEB 22, 2021
Drug Discovery & Development
Screening Macrocyclic Peptides
FEB 22, 2021
Screening Macrocyclic Peptides
Macrocyclic peptides are promising for pharmaceuticals for cancer—however, screening for them is challenging. Find ...
Loading Comments...